Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$3.45 -2.3%	$3.01	$2.46 ▼ $4.15	$295.25M	0.18	319,612 shs	444,473 shs
AVTE Aerovate Therapeutics	$9.19 -0.6%	$18.67	$54.95 ▼ $105.00	$266.37M	0.95	12,894 shs	4.17 million shs
NGNE Neurogene	$16.16 -2.5%	$17.33	$6.88 ▼ $74.49	$230.47M	1.57	246,333 shs	436,968 shs
SKYE Skye Bioscience	$4.11 -3.3%	$2.38	$1.14 ▼ $8.26	$127.31M	1.69	479,709 shs	7.48 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	-2.27%	+6.15%	+17.75%	+17.75%	+2.37%
AVTE Aerovate Therapeutics	-11.99%	-1.70%	+25.51%	-89.55%	-81.65%
NGNE Neurogene	-2.47%	-9.01%	-8.49%	+11.29%	-49.52%
SKYE Skye Bioscience	-3.29%	+90.28%	+106.02%	+119.08%	-46.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVIR Atea Pharmaceuticals	2.7559 of 5 stars	3.3	2.0	0.0	0.0	2.2	2.5	1.3
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	3.9481 of 5 stars	4.4	3.0	0.0	0.0	2.7	2.5	1.3
SKYE Skye Bioscience	2.3713 of 5 stars	3.5	4.0	0.0	0.0	3.2	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.50	Moderate Buy	$6.00	73.91% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
NGNE Neurogene	2.75	Moderate Buy	$46.17	185.68% Upside
SKYE Skye Bioscience	3.00	Buy	$16.60	303.89% Upside

Current Analyst Ratings Breakdown

Latest SKYE, AVIR, NGNE, and AVTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	SKYE Skye Bioscience	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/20/2025	SKYE Skye Bioscience	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00
5/13/2025	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $45.00
4/14/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$45.00 ➝ $16.00
4/11/2025	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$6.20 ➝ $6.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$5.20 per share	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
NGNE Neurogene	$930K	247.79	N/A	N/A	$20.89 per share	0.77
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	$2.25 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$168.38M	-$1.65	N/A	N/A	N/A	N/A	-31.26%	-29.27%	8/6/2025 (Estimated)
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	N/A	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
SKYE Skye Bioscience	-$26.57M	-$0.82	N/A	N/A	N/A	N/A	-53.92%	-48.58%	N/A

Latest SKYE, AVIR, NGNE, and AVTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AVIR Atea Pharmaceuticals	-$0.56	-$0.40	+$0.16	-$0.40	N/A	N/A
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	SKYE Skye Bioscience	-$0.31	-$0.28	+$0.03	-$0.28	N/A	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
SKYE Skye Bioscience	N/A	N/A	N/A	N/A	N/A

Latest SKYE, AVIR, NGNE, and AVTE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	19.94	19.94
AVTE Aerovate Therapeutics	N/A	8.78	8.78
NGNE Neurogene	N/A	21.03	21.03
SKYE Skye Bioscience	N/A	11.85	11.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
AVTE Aerovate Therapeutics	N/A
NGNE Neurogene	52.37%
SKYE Skye Bioscience	21.09%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	18.10%
AVTE Aerovate Therapeutics	24.90%
NGNE Neurogene	11.64%
SKYE Skye Bioscience	4.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	70	85.58 million	70.09 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
NGNE Neurogene	90	14.26 million	12.60 million	Optionable
SKYE Skye Bioscience	11	30.98 million	29.58 million	Optionable

SKYE, AVIR, NGNE, and AVTE Headlines

Recent News About These Companies

Skye Bioscience (NASDAQ:SKYE) Given "Market Outperform" Rating at JMP Securities

June 26 at 2:13 AM | americanbankingnews.com

Positive week for Skye Bioscience, Inc. (NASDAQ:SKYE) institutional investors who lost 53% over the past year

June 25 at 12:57 PM | finance.yahoo.com

Skye Bioscience Shares Nimacimab "Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th ...

June 24, 2025 | manilatimes.netM

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes ... - Morningstar

June 24, 2025 | morningstar.comM

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment - Nasdaq

June 24, 2025 | nasdaq.com

Skye Bioscience (NASDAQ:SKYE) Receives "Market Outperform" Rating from JMP Securities

June 24, 2025 | marketbeat.com

Skye Bioscience Launches "Anatomy of Progress" Video Series on Nimacimab Development for Obesity Treatment

June 23, 2025 | quiverquant.comQ

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

June 23, 2025 | globenewswire.com

Skye Bioscience (NASDAQ:SKYE) Trading 23.1% Higher - Should You Buy?

June 20, 2025 | marketbeat.com

Skye confirms phase 2 data on nimacimab for obesity expected later this year

June 19, 2025 | msn.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

June 17, 2025 | finance.yahoo.com

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

June 17, 2025 | globenewswire.com

Cantor Fitzgerald Weighs in on Skye Bioscience FY2026 Earnings

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Skye Bioscience FY2026 Earnings

June 10, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from Analysts

June 8, 2025 | marketbeat.com

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages

June 8, 2025 | marketbeat.com

Skye Bioscience (NASDAQ:SKYE) Trading Up 24% - Here's What Happened

May 31, 2025 | marketbeat.com

3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies

May 23, 2025 | zacks.com

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025 | globenewswire.com

Skye And Arecor Partner To Develop Advanced Nimacimab Formulation For Obesity Treatment

May 21, 2025 | nasdaq.com

Q&A: Next wave of obesity drugs may ‘afford a lot of advantages’

May 20, 2025 | healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

SKYE, AVIR, NGNE, and AVTE Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$3.45 -0.08 (-2.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.46 +0.01 (+0.43%)

As of 06/27/2025 04:34 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Aerovate Therapeutics NASDAQ:AVTE

$9.19 -0.06 (-0.65%)

As of 06/27/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Neurogene NASDAQ:NGNE

$16.16 -0.41 (-2.47%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$15.88 -0.28 (-1.70%)

As of 06/27/2025 05:45 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Skye Bioscience NASDAQ:SKYE

$4.11 -0.14 (-3.29%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.15 +0.04 (+0.97%)

As of 06/27/2025 07:58 PM Eastern

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time